Mounjaro®
Starting from £179.99/mo
Start journey Learn moreMounjaro does cause some reduction in muscle mass alongside fat loss, but the degree is lower than many people expect and can be reduced further with the right habits. Most weight loss (from any method) involves losing some lean tissue as well as fat. Tirzepatide is no exception, though trial data suggest it preserves a greater proportion of lean mass relative to fat than calorie restriction alone. These are prescription-only medicines, and a prescriber will talk through your individual circumstances before treatment begins.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
The biggest misconception circulating about Mounjaro and muscle loss is that tirzepatide strips muscle in a way that is unusual or dangerous compared with other routes to weight loss. It does not. When the body loses weight (whether through surgery, dieting, or medication) some lean tissue always comes with it. That is normal physiology, not a drug side effect.
What actually matters is the composition of the weight you lose: how much is fat versus how much is muscle. In the SURMOUNT-1 trial, which followed over 2,500 adults with obesity for 72 weeks, participants at the highest dose lost roughly 20–21% of body weight on average. Importantly, analyses of body composition data showed the majority of that reduction was adipose (fat) tissue. Lean mass losses occurred, but they were proportionally smaller than the fat losses, a pattern that compares favourably with calorie restriction programmes studied under similar conditions. You can read the published trial data via SURMOUNT-1 in the New England Journal of Medicine.
So the honest answer is: yes, some muscle loss is likely over a long course of treatment. No, it is not the dominant effect, and it is not unique to this drug.
Mounjaro activates both GIP and GLP-1 receptors, the only licensed weight-loss medicine in the UK to do so. There is emerging interest in whether GIP receptor activation has a role in muscle metabolism beyond appetite regulation, though this remains an active area of research rather than established fact. What is clearer is that the appetite reduction tirzepatide produces tends to make it easier for people to maintain protein intake as a proportion of a smaller total diet, which matters for lean tissue preservation.
Protein adequacy is one of the questions our clinical team at nume regularly raises with patients during aftercare: as overall food intake falls, it is easy to under-eat protein without realising it. A practical habit worth building early (one that takes under a minute) is checking the protein content on whatever you are about to eat, using the nutritional label, and aiming to keep that figure meaningful at every meal.
The broader picture of how tirzepatide works is covered on our tirzepatide overview page if you want the mechanism in more detail.
Resistance training is the most robustly evidenced strategy for limiting lean tissue loss during weight loss, including during GLP-1 treatment. It does not need to be intense or gym-based to have an effect, two sessions a week of bodyweight exercises, resistance bands, or free weights is enough to signal muscle maintenance to the body, according to general exercise physiology evidence.
The NHS weight-management guidance for people on injectable medicines specifically recommends combining treatment with increased physical activity, and resistance work sits within that recommendation. You can see how NHS England frames the lifestyle component in its guidance on weight-management injections.
One thing worth knowing: tirzepatide often reduces energy levels slightly in the early weeks of treatment, particularly around dose increases. This can make people feel less like exercising at precisely the point when it matters most. Starting with lower-intensity resistance work and building up is more sustainable than waiting until you feel ready for the gym.
There is more practical detail on lean mass and treatment on our page about Mounjaro and muscle loss, including what the body composition research shows across different dose levels.
If you are considering Mounjaro for weight management, muscle mass is a reasonable thing to think about, particularly if you are older (sarcopenia risk rises with age), very physically active, or have a health condition where muscle strength matters. None of those factors rules out treatment, but they are worth mentioning at consultation so your prescriber can take them into account. If you want a closer look at the evidence on this specific point, our page on whether Mounjaro affects muscles works through what the research currently shows.
It is also worth remembering that significant obesity itself is associated with poorer muscle quality and function over time. The net effect of effective weight loss treatment on physical capacity is positive for most people, even accounting for some reduction in lean tissue alongside fat. A related question we hear from people who are active or strength-focused is answered in more detail on our page covering whether you lose muscle mass on Mounjaro, which looks at how the numbers break down in practice.
The Mounjaro overview covers eligibility, the prescribing process and what the treatment involves in full. On the question of cost, the Mounjaro cost page sets out what private treatment involves and what a legitimate price includes. If you are ready to explore whether treatment is appropriate for you, check your eligibility with a free consultation, a GPhC-registered prescriber reads every submission the same day.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.